JPWO2023276869A1 - - Google Patents

Info

Publication number
JPWO2023276869A1
JPWO2023276869A1 JP2023531893A JP2023531893A JPWO2023276869A1 JP WO2023276869 A1 JPWO2023276869 A1 JP WO2023276869A1 JP 2023531893 A JP2023531893 A JP 2023531893A JP 2023531893 A JP2023531893 A JP 2023531893A JP WO2023276869 A1 JPWO2023276869 A1 JP WO2023276869A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023531893A
Other languages
Japanese (ja)
Other versions
JPWO2023276869A5 (cg-RX-API-DMAC7.html
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2023276869A1 publication Critical patent/JPWO2023276869A1/ja
Publication of JPWO2023276869A5 publication Critical patent/JPWO2023276869A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023531893A 2021-06-28 2022-06-24 Pending JPWO2023276869A1 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021106928 2021-06-28
PCT/JP2022/025259 WO2023276869A1 (ja) 2021-06-28 2022-06-24 血管新生阻害薬による治療後の予後予測方法および癌の併用療法

Publications (2)

Publication Number Publication Date
JPWO2023276869A1 true JPWO2023276869A1 (cg-RX-API-DMAC7.html) 2023-01-05
JPWO2023276869A5 JPWO2023276869A5 (cg-RX-API-DMAC7.html) 2025-05-09

Family

ID=84691826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023531893A Pending JPWO2023276869A1 (cg-RX-API-DMAC7.html) 2021-06-28 2022-06-24

Country Status (2)

Country Link
JP (1) JPWO2023276869A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023276869A1 (cg-RX-API-DMAC7.html)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011141279A (ja) * 2010-01-05 2011-07-21 Pfizer Inc 抗igf−ir癌療法のためのバイオマーカー
JP2014510265A (ja) * 2011-02-02 2014-04-24 アムジェン インコーポレイテッド Igf−1rの阻害に関する方法および組成物
US20140127193A1 (en) * 2011-05-05 2014-05-08 Duke University Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
US20160230234A1 (en) * 2013-09-17 2016-08-11 Agency For Science, Technology And Research Multigene Assay for Prognosis of Renal Cancer
JP2020522707A (ja) * 2017-06-04 2020-07-30 ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズRappaport Family Institute for Research in the Medical Sciences がん治療に対する個別化応答の予測方法およびそのキット

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011141279A (ja) * 2010-01-05 2011-07-21 Pfizer Inc 抗igf−ir癌療法のためのバイオマーカー
JP2014510265A (ja) * 2011-02-02 2014-04-24 アムジェン インコーポレイテッド Igf−1rの阻害に関する方法および組成物
US20140127193A1 (en) * 2011-05-05 2014-05-08 Duke University Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
US20160230234A1 (en) * 2013-09-17 2016-08-11 Agency For Science, Technology And Research Multigene Assay for Prognosis of Renal Cancer
JP2020522707A (ja) * 2017-06-04 2020-07-30 ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズRappaport Family Institute for Research in the Medical Sciences がん治療に対する個別化応答の予測方法およびそのキット

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABOU-ALFA GHASSAN K. ET AL.: "A Phase II Study of Cixutumumab (IMC-A12, NSC742460) in Advanced Hepatocellular Carcinoma", JOURNAL OF HEPATOLOGY, vol. 60, no. 2, JPN6022030408, February 2014 (2014-02-01), pages 319 - 324, ISSN: 0005880642 *
GIANNELLI GIANLUIGI ET AL.: "Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-", PLOS ONE, vol. 15, no. 3, JPN6022030409, 25 March 2020 (2020-03-25), pages 0222259, ISSN: 0005880643 *
HAMAGUCHI TETSUYA ET AL.: "Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with", CANCER SCIENCE, vol. 110, JPN6022030407, 21 October 2019 (2019-10-21), pages 3565 - 3572, ISSN: 0005880641 *

Also Published As

Publication number Publication date
WO2023276869A1 (ja) 2023-01-05

Similar Documents

Publication Publication Date Title
BR102022016638B1 (pt) Sistema de direção para tremonha autodescarregável e viga útil para o eixo dianteiro da tremonha
BR112022021777B1 (pt) Método para fabricar uma estrutura semicondutora e dispositivo semicondutor
BR102021016837A2 (cg-RX-API-DMAC7.html)
CN305800307S (zh) 手表连接器
CN305802647S (zh) 车载夜视仪(翻盖式高清)
CN305790149S (zh) 后视镜镜杆(jg-zpc840)
CN305750024S (zh) 电子耳温枪(2)
CN305764604S (zh) 窗帘杆装饰头(喇叭头)
CN305763528S (zh) 角几(慕尚-13a)
CN305780355S (zh) 模块化伺服驱动器立式测试平台
CN305802092S (zh) 可调电视固定支架(xd6116)
CN305755479S (zh) 洁厕具(多功能)
CN305795599S (zh) 前大灯
CN305767868S (zh) 鲨鱼双滑梯
CN305757523S (zh) 摆件(塘朗山)
CN305748994S (zh) 口杯(小狐狸)
CN305781421S (zh) 带查看歌单图形用户和界面的显示屏幕面板
CN305787328S (zh) 夹子(1031)
CN305758102S (zh) 充电器(d)
CN305753645S (zh) 包
CN305783304S (zh) 脱毛仪(ka-05)
CN305792336S (zh) 音乐盒(圣诞老人)
CN305791590S (zh) 扩展坞(Type_C4IN1)
CN305772858S (zh) 连排塑料软管(方形倒角)
CN305617429S (zh) 防丢器(挂绳)

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20231220

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20231220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260729